Resources with keywords: mRNA



Safety Monitoring of mRNA COVID-19 Vaccine Third Doses Among Children Aged 6 Months–5 Years — United States, June 17, 2022–May 7, 2023 (NEW 7/11, Website, Publication)
CDC/MMWR
9 June 2023

Hause AM, Marquez P, Zhang B, et al.

Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023 (Website, Regulatory)
CDC/MMWR
3 February 2023

Link-Gelles R, Ciesla AA, Roper LE, et al.

Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — United States, June 2021–February 2022 (NEW 5/6, Website, Publication)
CDC/MMWR
15 April 2022

Plumb ID, Feldstein LR, Barkley E, et al.

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 (NEW 3/7, Website, Publication)
CDC/MMWR
18 February 2022

Ferdinands JM, Rao S, Dixon BE, et al.

keywords: covid-19, Delta, mRNA, omicron
Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021 (NEW 11/2, Website, Publication)
CDC/MMWR
5 November 2021

Olson SM, Newhams MM, Halasa NB, et al.

What’s the research progress of mRNA vaccines for infectious diseases?
Medical Trend
24 October 2021
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses (NEW 8/3, Website, Publication)
JAMA
23 July 2021

Ilies Benotmane, Gabriela Gautier, Peggy Perrin, et al

Go to Top